[Drug-induced lupus].
Lovisetto
P
P
Mairano
D
D
Cargnino
M
M
Biarese
V
V
Marchi
L
L
Lerda
R
R
D000107:Acetylation; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000974:Antibodies, Antinuclear / Q000032:analysis; D000927:Anticonvulsants / Q000009:adverse effects; D001402:B-Lymphocytes / Q000276:immunology; D003937:Diagnosis, Differential; D006680:HLA Antigens / Q000235:genetics; D006801:Humans; D006830:Hydralazine / Q000009:adverse effects / Q000378:metabolism; D007538:Isoniazid / Q000009:adverse effects / Q000378:metabolism; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis / Q000276:immunology; D008213:Lymphocyte Activation; D010396:Penicillamine / Q000009:adverse effects; D011342:Procainamide / Q000009:adverse effects / Q000378:metabolism; D012460:Sulfasalazine / Q000009:adverse effects; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology
D000319:Adrenergic beta-Antagonists; D000974:Antibodies, Antinuclear; D000927:Anticonvulsants; D006680:HLA Antigens; D006830:Hydralazine; D012460:Sulfasalazine; D010396:Penicillamine; D011342:Procainamide; D007538:Isoniazid
Il lupus farmaco-indotto.